Galapagos NV (GLPG)
NASDAQ: GLPG · Real-Time Price · USD
28.83
+0.43 (1.53%)
May 6, 2026, 11:30 AM EDT - Market open
Galapagos NV Revenue
In the year 2025, Galapagos NV had annual revenue of 1.11B EUR with 303.50% growth. Galapagos NV had revenue of 900.82M in the quarter ending December 31, 2025, with 1,093.22% growth.
Revenue (ttm)
1.11B EUR
Revenue Growth
+303.50%
P/S Ratio
1.44
Revenue / Employee
1,993,280 EUR
Employees
558
Market Cap
1.88B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.11B | 836.60M | 303.50% |
| Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
| Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
| Dec 31, 2022 | 241.25M | 85.33M | 54.73% |
| Dec 31, 2017 | 155.92M | 4.31M | 2.84% |
| Dec 31, 2016 | 151.61M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 868.45M |
| Vericel | 276.26M |
| AnaptysBio | 234.60M |
| Zymeworks | 105.97M |
| Recursion Pharmaceuticals | 74.68M |
| Capricor Therapeutics | 11.13M |
| Taysha Gene Therapies | 9.77M |
| Inhibrx Biosciences | 1.30M |
GLPG News
- 5 days ago - Oversold Conditions For Galapagos (GLPG) - Nasdaq
- 7 days ago - Galapagos NV: Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026 - Finanz Nachrichten
- 7 days ago - Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026 - GlobeNewsWire
- 5 weeks ago - Galapagos NV Transcript: Collaboration - Transcripts
- 5 weeks ago - Galapagos Enters Framework Agreement With Gilead In Connection With Ouro Deal - Nasdaq
- 5 weeks ago - Galapagos NV: Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - Finanz Nachrichten
- 5 weeks ago - Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - GlobeNewsWire
- 5 weeks ago - Galapagos NV: Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings - Finanz Nachrichten